CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has engaged Vitale, Caturano & Company, Ltd as its independent auditor.
The audit committee of Biopure's board of directors made its selection after a review of audit firms that had expertise with public clients of Biopure's size and requirements.
Based in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. is a large, regional registered public accounting firm. Vitale, Caturano & Company replaces Ernst & Young, LLP.
Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.
SOURCE Biopure Corporation